Lead Product(s) : VRDN-001
Therapeutic Area : Immunology
Study Phase : IND Enabling
Sponsor : Fairmount Funds Management LLC
Deal Size : $91.0 million
Deal Type : Financing
miRagen Therapeutics, Inc. Announces Acquisition of Viridian Therapeutics, Inc.
Details : Company plans to use private placement financing proceeds of $91 million to advance multiple compounds through phase 2 proof of concept studies in TED and to expand its orphan disease pipeline.
Product Name : AVE-1642
Product Type : Antibody
Upfront Cash : Undisclosed
October 28, 2020
Lead Product(s) : VRDN-001
Therapeutic Area : Immunology
Highest Development Status : IND Enabling
Sponsor : Fairmount Funds Management LLC
Deal Size : $91.0 million
Deal Type : Financing